Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Silence Therapeutics (SLN) Net Cash Flow: 2018-2024

Historic Net Cash Flow for Silence Therapeutics (SLN) over the last 7 years, with Dec 2024 value amounting to $52.5 million.

  • Silence Therapeutics' Net Cash Flow rose 172.41% to $40.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.1 million, marking a year-over-year decrease of 110.78%. This contributed to the annual value of $52.5 million for FY2024, which is 2866.70% up from last year.
  • Silence Therapeutics' Net Cash Flow amounted to $52.5 million in FY2024, which was up 2,866.70% from $1.8 million recorded in FY2023.
  • In the past 5 years, Silence Therapeutics' Net Cash Flow registered a high of $63.6 million during FY2021, and its lowest value of -$25.0 million during FY2022.
  • For the 3-year period, Silence Therapeutics' Net Cash Flow averaged around $9.8 million, with its median value being $1.8 million (2023).
  • In the last 5 years, Silence Therapeutics' Net Cash Flow tumbled by 139.27% in 2022 and then surged by 2,866.70% in 2024.
  • Silence Therapeutics' Net Cash Flow (MRY) stood at $14.4 million in 2020, then soared by 339.86% to $63.6 million in 2021, then crashed by 139.27% to -$25.0 million in 2022, then surged by 107.09% to $1.8 million in 2023, then skyrocketed by 2,866.70% to $52.5 million in 2024.
  • Its last three reported values are $52.5 million in FY2024, $1.8 million for FY2023, and -$25.0 million during FY2022.